
-
Bioatla Inc NasdaqGM:BCAB BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Location: 11085 Torreyana Road, San Diego, CA, 92121, United States | Website: https://www.bioatla.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-8.968M
Cash
32.36M
Avg Qtr Burn
-14.35M
Short % of Float
9.90%
Insider Ownership
10.90%
Institutional Own.
32.92%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Evalstotug (BA3071) + Pembrolizumab Details Cancer, Melanoma | Phase 3 Initiation | |
Ozuriftamab vedotin (BA3021) (ROR2-ADC) Details Cancer, Melanoma | Phase 2 Data readout | |
Ozuriftamab vedotin (BA3021) (CAB-ROR2-ADC) Details Head and neck squamous cell carcinoma | Phase 2 Update | |
mecbotamab vedotin (BA3011) (anti-AXL ADC) Details Solid tumor/s, Soft tissue sarcoma, Non-small cell lung carcinoma, Bone sarcoma, Cancer | Phase 2 Update | |
CAB-EpCAM x CAB-CD3 TCE (BA3182) Details Cancer, Carcinoma | Phase 1/2 Data readout | |
Evalstotug (BA3071) (CAB anti-CTLA-4 antibody) w/ nivolumab Details Solid tumor/s, Cancer | Phase 1/2 Update |